Cargando…
Synthesis and validation of click-modified NOD1/2 agonists
NOD1 and NOD2 sense small bacterial peptidoglycan fragments, often called muropeptides, that access the cytosol. These muropeptides include iE-DAP and MDP, the minimal agonists for NOD1 and NOD2, respectively. Here, we synthesized and validated alkyne-modified muropeptides, iE-DAP-Alk and MDP-Alk, f...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10621468/ https://www.ncbi.nlm.nih.gov/pubmed/37828863 http://dx.doi.org/10.1177/17534259231207198 |
_version_ | 1785130391480303616 |
---|---|
author | Bharadwaj, Ravi Anonick, Madison V. Jaiswal, Swati Mashayekh, Siavash Brown, Ashley Wodzanowski, Kimberly A. Okuda, Kendi Silverman, Neal Grimes, Catherine L. |
author_facet | Bharadwaj, Ravi Anonick, Madison V. Jaiswal, Swati Mashayekh, Siavash Brown, Ashley Wodzanowski, Kimberly A. Okuda, Kendi Silverman, Neal Grimes, Catherine L. |
author_sort | Bharadwaj, Ravi |
collection | PubMed |
description | NOD1 and NOD2 sense small bacterial peptidoglycan fragments, often called muropeptides, that access the cytosol. These muropeptides include iE-DAP and MDP, the minimal agonists for NOD1 and NOD2, respectively. Here, we synthesized and validated alkyne-modified muropeptides, iE-DAP-Alk and MDP-Alk, for use in click-chemistry reactions. While it has long been known that many cell types respond to extracellular exposure to muropeptides, it is unclear how these innate immune activators access their cytosolic innate immune receptors, NOD1 and NOD2. The subcellular trafficking and transport mechanisms by which muropeptides access these cytosolic innate immune receptors are a major gap in our understanding of these critical host responses. The click-chemistry-enabled agonists developed here will be particularly powerful to decipher the underlying cell biology and biochemistry of NOD1 and NOD2 innate immune sensing. |
format | Online Article Text |
id | pubmed-10621468 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-106214682023-11-03 Synthesis and validation of click-modified NOD1/2 agonists Bharadwaj, Ravi Anonick, Madison V. Jaiswal, Swati Mashayekh, Siavash Brown, Ashley Wodzanowski, Kimberly A. Okuda, Kendi Silverman, Neal Grimes, Catherine L. Innate Immun Original Articles NOD1 and NOD2 sense small bacterial peptidoglycan fragments, often called muropeptides, that access the cytosol. These muropeptides include iE-DAP and MDP, the minimal agonists for NOD1 and NOD2, respectively. Here, we synthesized and validated alkyne-modified muropeptides, iE-DAP-Alk and MDP-Alk, for use in click-chemistry reactions. While it has long been known that many cell types respond to extracellular exposure to muropeptides, it is unclear how these innate immune activators access their cytosolic innate immune receptors, NOD1 and NOD2. The subcellular trafficking and transport mechanisms by which muropeptides access these cytosolic innate immune receptors are a major gap in our understanding of these critical host responses. The click-chemistry-enabled agonists developed here will be particularly powerful to decipher the underlying cell biology and biochemistry of NOD1 and NOD2 innate immune sensing. SAGE Publications 2023-10-13 2023-11 /pmc/articles/PMC10621468/ /pubmed/37828863 http://dx.doi.org/10.1177/17534259231207198 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Articles Bharadwaj, Ravi Anonick, Madison V. Jaiswal, Swati Mashayekh, Siavash Brown, Ashley Wodzanowski, Kimberly A. Okuda, Kendi Silverman, Neal Grimes, Catherine L. Synthesis and validation of click-modified NOD1/2 agonists |
title | Synthesis and validation of click-modified NOD1/2 agonists |
title_full | Synthesis and validation of click-modified NOD1/2 agonists |
title_fullStr | Synthesis and validation of click-modified NOD1/2 agonists |
title_full_unstemmed | Synthesis and validation of click-modified NOD1/2 agonists |
title_short | Synthesis and validation of click-modified NOD1/2 agonists |
title_sort | synthesis and validation of click-modified nod1/2 agonists |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10621468/ https://www.ncbi.nlm.nih.gov/pubmed/37828863 http://dx.doi.org/10.1177/17534259231207198 |
work_keys_str_mv | AT bharadwajravi synthesisandvalidationofclickmodifiednod12agonists AT anonickmadisonv synthesisandvalidationofclickmodifiednod12agonists AT jaiswalswati synthesisandvalidationofclickmodifiednod12agonists AT mashayekhsiavash synthesisandvalidationofclickmodifiednod12agonists AT brownashley synthesisandvalidationofclickmodifiednod12agonists AT wodzanowskikimberlya synthesisandvalidationofclickmodifiednod12agonists AT okudakendi synthesisandvalidationofclickmodifiednod12agonists AT silvermanneal synthesisandvalidationofclickmodifiednod12agonists AT grimescatherinel synthesisandvalidationofclickmodifiednod12agonists |